comparativestudiesofhuperzineadonepezilandrivastigmineonbrainacetylcholinedopaminenorepinephrineand5hydroxytryptaminelevelsinfreelymovingrats
文献类型：期刊论文
| 作者 | Xican Tang ; Yanqi Liang
|
| 刊名 | actapharmacologicasinica
 |
| 出版日期 | 2006 |
| 卷号 | 27期号:9页码:1127 |
| 关键词 | SPATIAL WORKING-MEMORY CHOLINESTERASE INHIBITOR ALZHEIMERS-DISEASE EXTRACELLULAR ACETYLCHOLINE HIPPOCAMPAL ACETYLCHOLINE CHOLINERGIC SYSTEM PREFRONTAL CORTEX AGED RATS IN-VIVO 2ND-GENERATION huperzine A donepezil rivastigmine acetylcholine dopamine norepinephrine 5-hydroxy tryptamine Alzheimer's disease rats |
| ISSN号 | 1671-4083 |
| DOI | 10.1111/j.1745-7254.2006.00411.x |
| 英文摘要 | Aim: To assess the effects of cholinesterase inhibitors huperzine A, donepezil and rivastigmine on cerebral neurotransmitters in the cortex and hippocampus in freely-moving rats. Methods: Double-probe cerebral microdialysis and HPLC with electrochemical detection were used to detect neurotransmitters. Results: Our results showed that huperzine A (0.25, 0.5, and 0.75 mu mol/kg, po) dose-dependently elevated extracellular acetylcholine (ACh) levels in the medial prefrontal cortex (mPFC) and hippocampus. Oral administration of donepezil (5.4 mu mol/kg) or rivastigmine (1 mu mol/kg) also elicited significant increases in ACh in the MPFC and hippocampus. The time course of cortical acetylcholinesterase (AChE) inhibition with the 3 inhibitors mirrored the increases of ACh at the same dose. The marked elevation of ACh after oral administration of huperzine A (0.5 mu mol/kg) and donepezil (5.4 mu mol/kg) was associated with a significantly increased release of dopamine (DA) in the mPFC or hippocampus. None of the 3 inhibitors affected norepinephrine (NE) and 5-hydroxytryptamine (5-HT) levels in the mPFC and hippocampus. The effects of huperzine A and rivastigmine did not depend on the route of administration, but donepezil was less efficacious by the oral route than by ip injection. The ability of huperzine A to increase ACh levels was unchanged when tests were performed after multiple oral administration of the drug at 0.5 pmol/kg, once per day for 30 d. Conclusion: The present findings showed that, in molar terms, huperzine A had similar potency on increasing mPFC ACh and DA levels as compared to the 11- and 2-fold dosages of donepezil and rivastigmine, respectively, and had longer lasting effects after oral dosing. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/283117]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 中国科学院上海药物研究所 |
| 推荐引用方式 GB/T 7714 | Xican Tang,Yanqi Liang. comparativestudiesofhuperzineadonepezilandrivastigmineonbrainacetylcholinedopaminenorepinephrineand5hydroxytryptaminelevelsinfreelymovingrats[J]. actapharmacologicasinica,2006,27(9):1127. |
| APA | Xican Tang,&Yanqi Liang.(2006).comparativestudiesofhuperzineadonepezilandrivastigmineonbrainacetylcholinedopaminenorepinephrineand5hydroxytryptaminelevelsinfreelymovingrats.actapharmacologicasinica,27(9),1127. |
| MLA | Xican Tang,et al."comparativestudiesofhuperzineadonepezilandrivastigmineonbrainacetylcholinedopaminenorepinephrineand5hydroxytryptaminelevelsinfreelymovingrats".actapharmacologicasinica 27.9(2006):1127. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。